Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow.
Ontology highlight
ABSTRACT: Estrogen receptor-positive (ER+) breast cancer can recur up to 20 years after initial diagnosis. Delayed recurrences arise from disseminated tumors cells (DTCs) in sites such as bone marrow that remain quiescent during endocrine therapy and subsequently proliferate to produce clinically detectable metastases. Identifying therapies that eliminate DTCs and/or effectively target cells transitioning to proliferation promises to reduce risk of recurrence. To tackle this problem, we utilized a 3D co-culture model incorporating ER+ breast cancer cells and bone marrow mesenchymal stem cells to represent DTCs in a bone marrow niche. 3D co-cultures maintained cancer cells in a quiescent, viable state as measured by both single-cell and population-scale imaging. Single-cell imaging methods for metabo
SUBMITTER: Buschhaus JM
PROVIDER: S-EPMC7442734 | biostudies-literature | 2020 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA